Cohort 1 will start from 23 June 2025 however there is currently no local service in place.
Criteria for eligibility:
At least 4 of the 5 health conditions listed below plus a BMI of at least 40*.
- type 2 diabetes mellitus
- high blood pressure (hypertension)
- heart disease (cardiovascular disease)
- obstructive sleep apnoea
- abnormal blood fats (dyslipidaemia)
*Due to an increased risk of health conditions at lower BMI thresholds in these populations, the BMI applied to assess eligibility for Tirzepatide must be adjusted by 2.5 kg/m2 in people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds to ensure equitable clinical prioritisation and access to appropriate treatment.
Please do not submit requests unless you qualify as stated above.
For more information, please the see the Tirzepatide (Mounjaro®) FAQs (PDF).